A Frankfurt-based pharmaceutical company purchased 100 Bitcoins in May 2025, valued at approximately €10 million. This decision aims to expand its digital asset reserves.
Investment Strategy in Bitcoin
The company began its Bitcoin investment strategy in 2020. With this recent acquisition, it reinforces its commitments in this area.
Reasons for Acquisition
Managing Director Dominik Evertz described Bitcoin as a scarce, globally tradable asset that strengthens long-term financial stability. He noted that this asset complements the company’s reserves and aligns with its future-focused strategy.
Company's Future and Bitcoin
The company plans to continue strengthening its position in the digital asset market, viewing Bitcoin as an important resource for securing a sustainable financial future.
The recent acquisition of 100 Bitcoins highlights the growing interest in digital assets among traditional companies and signifies a shift towards diversifying reserves.
